ArticlePLOS global public health2025
Distribution and determinants of COVID-19 seroprevalence in a hard-to-access health district in Mali.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARS-CoV-2 antibody seroprevalence in unvaccinated medical students, Bamako, Mali: a cross-sectional study by hospital exposure level.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In November 2023, three years after the onset of the pandemic, Mali officially recorded 33,160 confirmed COVID-19 cases and 743 related deaths. Tombouctou health district, following Bamako, the capital city, emerged as the second major hotspot with over 532 confirmed cases. However, these figures likely underestimate the true scale of the epidemic due to limited healthcare access and diagnostic capacity. This study aimed to describe the early trajectory of the epidemic, estimate seroprevalence, and identify factors associated with COVID-19 in the Tombouctou health district. A multi-level study was conducted in January 2021. First, the epidemic dynamics in Tombouctou were analyzed, estimating the basic reproduction number (R0) using daily case time series. Additionally, a cross-sectional survey was conducted, involving 419 households and 1102 participants, allowing for seroprevalence estimation by age and gender. A face-to-face questionnaire collected information on living conditions and knowledge, attitudes, behaviors and practices, regarding the epidemic. Factors associated with SARS-CoV-2 seropositivity were determined using generalized additive mixed models (GAMMs), adjusted to the variable under study and the level of analysis. We estimated an R0 of 2.08 [1.46-2.93]. The crude seroprevalence of SARS-CoV-2 was 33.5% (309/923, 95% CI: 30.4% to 36.6%). Living in a household where someone had been diagnosed with COVID-19 [Incidence Rate Ratio (IRR)=5.47; 95% CI (4.51 to 6.64)], traditionally wealth households [IRR = 2.02; 95% CI (1.23-3.33)], modernly wealth households [IRR = 1.33; 95% CI (1.02 - 1.72)], and older age (per year) [Adjusted Odds Ratio (AOR)=1.02 (1.00 to 1.03)] were significantly associated with seropositivity. Our analysis highlighted the active circulation of SARS-CoV-2 in Tombouctou, with higher seroprevalence observed among people from wealth households, as well as older age groups. The findings underscore the need for tailored and targeted approach focusing on specific households, demographics and settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.